EP Patent

EP4206212A4 — SGLT-2 AND SARCOSINE INHIBITOR COCRYSTAL, PROCESS FOR PREPARATION THEREFOR AND USE THEREOF

Assigned to Beijing Creatron Institute of Pharmaceutical Research Co Ltd · Expires 2024-05-22 · 2y expired

What this patent protects

Patent listed against Farxiga.

Drugs covered by this patent

Patent Metadata

Patent number
EP4206212A4
Jurisdiction
EP
Classification
—
Expires
2024-05-22
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Creatron Institute of Pharmaceutical Research Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.